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Summary. Background: Patients with colorectal cancer are
at high risk of developing venous thromboembolism
(VTE), and recent international guidelines have advised
extended prophylaxis for some of these patients following
surgery or during chemotherapy. However, our under-
standing of which patients are at increased risk, and to
what extent, is limited. Objectives: To determine absolute
and relative rates of VTE among patients with colorectal
cancer according to Dukes stage, surgical intervention,
and chemotherapy. Methods: We analyzed data from four
linked databases from 1997 to 2006: the Clinical Practice
Research Datalink, linked to Hospital Episode Statistics,
Cancer Registry data, and Office for National Statistics
cause of death data, all from England. Rates were com-
pared by the use of Cox regression. Results: There were
10 309 patients with colorectal cancer, and 555 developed
VTE (5.4%). The incidence varied by Dukes stage, being
three-fold higher among Dukes D patients than among
Dukes A patients (hazard ratio [HR] 3.08, 95% confi-
dence interval [CI] 1.95–4.84), and 40% higher for those
receiving chemotherapy than for those not receiving che-
motherapy (HR 1.39, 95% CI 1.14–1.69). The risk fol-
lowing surgery varied by stage of disease and
chemotherapy, with Dukes A patients having a low inci-
dence of VTE (0.74%; 95% CI 0.28–1.95) at 6 months,
with all events occurring within 28 days of surgery, as
compared with Dukes B and Dukes C patients, whose
risk at 6 months was ~ 2%. Conclusion: Twenty-eight
days of prophylaxis following surgery for colorectal
cancer is appropriate for Dukes A patients. However,
Dukes B and Dukes C patients receiving postoperative
chemotherapy have a longer duration of risk.
Keywords: chemotherapy; colorectal cancer; colorectal
surgery; incidence; venous thromboembolism.
Introduction
Patients undergoing treatment for colorectal cancer are at
a high risk of developing venous thromboembolism
(VTE) shortly after diagnosis, and this risk appears to
vary with severity of disease [1]. This represents a signifi-
cant source of morbidity and mortality [2], and, in an
attempt to reduce the incidence among this patient group,
international guidance now recommends 28 days of post-
operative thromboprophylaxis for patients with colorectal
cancer [2]. However, the authors of these guidelines did
highlight the fact that our understanding of which
patients are at increased risk, what the magnitude of this
increased risk is, and for how long this risk is elevated, is
limited [2]. Only by understanding how these factors
influence risk and for how long the risk lasts will we be
able to identify the right patient groups in which to inter-
vene with appropriate preventive measures [3]. Unfortu-
nately, the influence on VTE risk of stage of colorectal
cancer in combination with therapies, including surgery
and chemotherapy, remains very unclear. The studies that
have reported information on this have focused on high-
risk populations, such as those receiving chemotherapy
[4,5], have combined data on stage with other cancer
types [6], or have used limited staging, such as local,
regional, and metastatic [7], rather than the internation-
ally recognized Dukes system. The one available study
reporting incidence rates by stage (0–IV) [8] showed a
graded increase in risk, with worsening disease with addi-
tional risk among those receiving palliative chemotherapy.
Inevitably, this trend could be explained by the surgical
intervention and chemotherapy regimens received by these
patients, which are dependent on stage of disease
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[3,6,9–11]. In addition, contradictory findings have been
reported for surgically treated patients, with some sug-
gesting an increase in risk and others a decrease. These
studies highlight the problem of the selection bias inher-
ent in studying VTE risk, because, for example, Dukes D
patients will not be undergoing surgery with curative
intent, in contrast to Dukes A, B and C patients. Fur-
thermore, no previous studies have quantified risk from
date of surgery, meaning that their results are not easy to
translate into clinically meaningful risks, as most guide-
lines advocate commencement of prophylaxis following
surgical intervention.
The aim of this study, therefore, was to use a large,
population-based cohort study to determine the risk of
VTE and its duration among all patients with a diagnosis
of colorectal cancer, taking account of how Dukes stage
of disease, surgical intervention and chemotherapy
received interact, using nationwide primary-care and sec-
ondary-care electronic medical data linked to cancer
registries from England.
Methods
Patients and data sources
Our data sources have been described in detail in previ-
ous work [12]. Briefly, these were all from England, and
comprised a primary-care database (the Clinical Practice
Research Datalink [CPRD]), a secondary-care database
that contains data from all inpatient hospital admissions
in England (Hospital Episode Statistics [HES]), a cancer
registry database (National Cancer Intelligence Network),
and death certificate data from the Office for National
Statistics (ONS). These databases were linked and anony-
mized by the CPRD, with the linked data covering ~ 4%
of the population of England. The study had approval
from the Independent Scientific Advisory Committee
approval board, which provides scientific advice to the
Medicines and Healthcare Products Regulatory Agency
(MHRA) on study design, and advises whether further
approval is required from the Multi-centre Research Eth-
ics Committee outside the MHRA’s current approval for
observational studies.
Cohort identification
The cohort was selected from the cancer registry data,
and additional information regarding outcome definition
and other exposures were identified in the relevant linked
primary-care (CPRD) and secondary-care (HES) data.
We selected patients who had a colorectal cancer diagno-
sis in the cancer registry data (ICD-10 sections C18–20,
excluding C18.1 – ‘Appendix’), between 1 April 1997 and
31 December 2006. Patients were followed up until they
developed a VTE event, died, left a participating general
practice, or 31 December 2010, whichever was earliest.
The earliest date recorded in the cancer registry was used
to determine the date of cancer diagnosis. Patients were
excluded if they were: < 18 years of age, not in a linked
general practice, diagnosed with colorectal cancer outside
of the CPRD and HES registration dates, diagnosed in
the first year of registration at a participating general
practice, or had a VTE prior to the first cancer diagnosis.
Exposures
Cancer stage and grade were determined by using data
from the cancer registry database, where stage was
recorded in various classification systems, including TNM
numerical stage (I–IV) (41.1%), Dukes stage (54.8%),
and the individual components of the TNM stage (4.1%).
By use of the numerical data and TNM data, patients
were recategorized into Dukes stages (A, B, C, and D) if
they were not already recorded as such. Most could be
directly translated from the numerical stage data, with
the exception of patients only recorded as numeric stage I
without TNM staging data (whose modified Dukes stage
was ambiguous as recorded by the Astler–Coller classifi-
cation) [13]. These patients were excluded from analyses
involving stage. Comorbidity was determined from gen-
eral practitioner records, and classified according to the
Charlson index [14], excluding cancer as a comorbidity.
Survival by cancer stage was determined from the linked
ONS mortality data, and was measured from the date of
cancer diagnosis for all analyses involving death. Surgical
procedures were defined from hospital episodes with an
associated Office of Population Census and Surveys Clas-
sification of Interventions and Procedures (OPCS) code
for colorectal surgery. Chemotherapy events were simi-
larly determined by the use of OPCS codes.
Outcome definition
VTE diagnoses were determined from medical codes in
the CPRD and HES. These were considered to be valid
VTE events if supported by either: a prescription for an
anticoagulant or other evidence of treatment in an antico-
agulation clinic (such as a medical code) between 15 days
before and 90 days after the VTE diagnosis; or a date of
death within 30 days of the event. Additionally, an under-
lying cause of death of VTE was included as evidence of
VTE diagnosis. Only the first validated instance of VTE
was included in the analysis. The definition from primary-
care data alone has been validated previously [15].
Statistical methods
Person-time at risk commenced at the time of cancer diag-
nosis for our overall analysis. First, we described the basic
characteristics of our cohort and 5-year survival by Dukes
stage. Absolute rates of VTE (per 1000 person-years) were
then calculated by dividing the number of people with VTE
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by the person-time at risk. This was performed overall and
then separately for each exposure of interest. A Cox propor-
tional hazards model was then created to include all expo-
sures, to estimate hazard ratios (HRs) and 95% confidence
intervals (CIs). We then evaluated the risk of VTE by Dukes
stage and according to whether or not patients had under-
gone surgery by stratifying our analysis by these factors.
Following this analysis, it was apparent that risks varied
markedly according to stage, so, to evaluate the interaction
between Dukes stage, surgical intervention, and chemother-
apy, we restricted our cohort to only those patients under-
going surgery with the assumption of curative intent (i.e.
Dukes A, B and C patients undergoing surgery). We then
reset our follow-up time to start from the date of surgery.
Among this restricted cohort, we examined the interaction
between chemotherapy and Dukes stage while adjusting for
other covariates, using a likelihood ratio test, and we pres-
ent stratified adjusted HRs from this analysis. Following
this, among the surgical cohort, we carried out an analysis
of cumulative incidence over the first 6 months of follow-up
stratified by Dukes stage (A, B, and C) and chemotherapy,
to illustrate how the absolute rates varied by these variables.
Data management and all analyses were performed with
STATA 11 (Statacorp, College Station, TX, USA).
Results
In the 10 years between 1997 and 2006, 10 309 colorectal
cancer patients were identified from cancer registry data
(Table 1). The median age at diagnosis was 74 years, and
the median follow-up time was 2.2 years. VTE occurred
in 555 cases, leading to a rate of 15.8 per 1000 person-
years (95% CI 14.5–17.1). Cancer stage was determinable
in 71.7% of patients. Among those with a known stage,
8.8% had Dukes A, a large majority had Dukes B and C
(37.2% and 33.8%, respectively), and 20.2% had
Dukes D. In total, 7407 (71.8%) patients underwent sur-
gery, with 25% of these patients receiving chemotherapy
following surgery, and the greatest proportion of chemo-
therapy being received by Dukes C patients. Among
those not undergoing surgery, 338 (11.6%) received palli-
ative chemotherapy. (Fig. 1 shows the distribution of
stage by surgery and chemotherapy.) Among patients
whose Dukes stage could not be determined, 6% had an
ambiguous Dukes stage (recorded only as numerical
stage I) and were excluded from analyses involving stage.
The overall 5-year survival rate in our cohort was 43.9%,
and this varied by stage, with Dukes A patients having
the most favorable survival and Dukes D the worst
(Table S1). Those with an undetermined stage also had
poor survival.
VTE rate varied substantially by stage (Table 2;
Fig. 2), with Dukes A patients having the lowest absolute
rate (7.3 per 1000 person-years, 95% CI 5.0–10.7) and
Dukes D patients the highest (41.3 per 1000 person-years,
95% CI 33.4–51.2). We observed that the rates seemed to
be similar in the first few months after diagnosis, and
then subsequently diverged. The effects of stage were
independent of other measured variables, as shown in the
multivariate Cox model (Table 2), with Dukes D patients
having a more than three-fold greater risk of VTE than
Dukes A patients (HR 3.1, 95% CI 2.0–4.8). From this
analysis, it was apparent there were no statistically signifi-
cant differences in VTE rate between tumor grades in the
multivariate model. Overall, patients undergoing surgery
had a similar rate of VTE as those not undergoing sur-
gery (HR 0.97, 95% CI 0.77–1.22). However, this effect
varied according to how patients were admitted for the
first operation, as patients with an emergency admission
had a higher rate of VTE than those with an elective
admission (HR 1.43, 95% CI 1.15–1.78). There was a
significantly higher rate of VTE in those receiving
Table 1 Numbers of patients by patient characteristics
No VTE % VTE %
Total 9754 555
Sex
Male 5241 53.7 312 56.2
Female 4513 46.3 243 43.8
Age bands (years)
< 40 103 1.1 6 1.1
40–49 365 3.7 27 4.9
50–59 1207 12.4 79 14.2
60–69 2240 23.0 163 29.4
70–79 3358 34.4 204 36.8
≥ 80 2481 25.4 76 13.7
Comorbidities
0 4724 48.4 257 46.3
1 2597 26.6 156 28.1
2 1371 14.1 88 15.9
3 628 6.4 32 5.8
4 238 2.4 13 2.3
5 85 0.9 6 1.1
6 72 0.7 2 0.4
≥7 39 0.4 1 0.2
Smoking
No 2997 30.7 192 34.6
Yes 744 7.6 42 7.6
Ex-smoker 2052 21.0 134 24.1
Unknown 3961 40.6 187 33.7
BMI
Underweight 168 1.7 9 1.6
Ideal 2083 21.4 118 21.3
Overweight 2055 21.1 141 25.4
Obese 687 7.0 44 7.9
Morbidly obese 181 1.9 21 3.8
Missing 4580 47.0 222 40.0
Surgery
Elective 5216 53.5 337 60.7
Emergency 1707 17.5 115 20.7
Other/unknown 31 0.3 1 0.2
None 2800 28.7 102 18.4
Chemotherapy
No 7818 80.2 370 66.7
Yes 1936 19.8 185 33.3
BMI, body mass index; VTE, venous thromboembolism.
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chemotherapy than in those who not receiving chemother-
apy (HR 1.39, 95% CI 1.14–1.69). A number of the other
recognized risk factors (smoking, body mass index [BMI],
age, and comorbidity) appeared to have relatively little
influence on the rate of VTE in this group (Table 2).
Although there was a slight trend observed for BMI (with
the highest rate in morbidly obese patients), this trend
was non-significant (P = 0.074).
When we stratified our analysis by stage of disease and
surgical intervention, the influence of surgery on the rate
of VTE appeared to vary according to the stage of cancer
(Fig. 3). In Dukes A patients, the VTE rate was higher in
patients undergoing surgery, whereas in Dukes D patients
the rate was higher in those not undergoing surgery. Sub-
sequent analyses were all carried out among patients who
had undergone surgery with the assumption of curative
intent (i.e. Dukes A, B and C patients). These results are
presented in Tables 3 and 4. When we fitted our model
with an interaction term between stage of disease and
chemotherapy, there was some evidence of an interaction
(likelihood ratio test, P < 0.047). The stratified HRs show
that Dukes B and C patients receiving chemotherapy had
a two-fold increase in risk of VTE as compared with
Dukes B patients not receiving chemotherapy (Table 3),
whereas Dukes A patients had no increase in risk.
Table 4 shows the incidence of VTE by time since sur-
gery, stratified by chemotherapy and Dukes stage, and
limited to those undergoing surgery. The whole popula-
tion and this subcohort were similar with respect to gen-
der (46.5% and 45.8% female, respectively), age (median
ages of 74 and 73 years), BMI (median of 25.7 kg m2
for both), and Charlson comorbidity score (mean of 0.70
for both). Table 4 shows that the incidence of VTE was
lowest in Dukes A patients undergoing surgery, and that
their risk was confined to the first 28 days following sur-
gery. In contrast, in Dukes B and C patients receiving
chemotherapy following surgery, the risk of VTE per-
sisted for 6 months following surgery (Table 4), with the
highest cumulative incidence being observed in Dukes C
patients receiving chemotherapy (2.5% at 6 months).
Discussion
Summary of findings
Overall, 5.4% of our cohort of colorectal cancer patients
developed a VTE during follow-up, with an absolute rate
of 15.8 per 1000 person-years. Increasing Dukes stage was
associated with an increased risk of developing VTE, with
Dukes D patients having the highest absolute rate (41.3
per 1000 person-years, 95% CI 33.4–51.2), corresponding
to a three-fold increase in risk as compared with Dukes A
patients. However, these risks were dependent on surgical
intervention and chemotherapy. Among patients undergo-
ing surgery with curative intent (Dukes A, B and C
patients), Dukes B and C patients receiving chemotherapy
had an approximately two-fold increase in risk of develop-
ing VTE as compared with Dukes A and B patients not
receiving chemotherapy. Analysis of the risk following sur-
gery when stratified by stage, adjuvant chemotherapy and
time since surgery demonstrated that Dukes A patients
had a low absolute risk that did not extend beyond the first
28 days following surgery. Dukes B and C patients receiv-
ing chemotherapy had a persistent risk of VTE that
All Patients
Surgery
Chemotherapy: Non-chemo: Non-chemo:Chemotherapy:
338 (11.6)
Dukes A-4 (11.8) Dukes A-85 (3.3)
Dukes B-245 (9.6)
Dukes C-212 (8.3)
Dukes D-570 (22.2)
Dukes B-28 (8.3)
Dukes C-53 (15.7)
Dukes D-116 (34.3)
Unknown-137 (40.5) Unknown-1452 (56.6)
1783 (24.1) 5624 (75.9) 2564 (88.4)
Dukes A-53 (3.0) Dukes A-499 (8.9)
Dukes B-376 (21.1) Dukes B-2086 (37.1)
Dukes C-1430 (25.4)
Dukes D-538 (9.6)
Dukes C-841 (47.2)
Dukes D-266 (14.9)
Unknown-247 (13.9) Unknown-1071 (19.0)
Non-Surgery
2902 (28.2)7407 (71.8)
10 309
Fig. 1. Distribution of patients by surgery, chemotherapy, and stage of disease.
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extended to at least 6 months in the postoperative period.
Our findings suggest that the current recommendation of a
28-day period of thromboprophylaxis among colorectal
cancer patients undergoing major abdominal surgery with
high-risk features, which would encompass all of our
patients, should be altered to take account of variation by
disease stage and identification of those patients receiving
chemotherapy who may benefit from an extension of pro-
phylaxis [16,17].
Strengths and limitations
Our study used linked data to identify patients with colo-
rectal cancer from population-based cancer registry data,
Table 2 Rates and cumulative incidence of venous thromboembolism (VTE) and multivariate Cox modeling for VTE risk factors from time of
diagnosis with colorectal cancer
Events
Person-
time
(1000s of
years)
Cumulative incidence Cox model
180 days from diagnosis 2 years from diagnosis
HR 95% CI
Events
(0–180 days) Cumulative%
Events
(0.5–2 years) Cumulative%
Site
Colon 358 21.2 135 2.52 97 4.91 Reference
Rectum 161 11.0 69 2.03 60 4.22 0.92 0.75–1.11
Dukes
A 26 3.6 7 1.11 2 1.45 Reference
B 141 13.4 41 1.59 41 3.37 1.30 0.85–1.98
C 186 9.3 60 2.59 58 5.54 2.07 1.36–3.14
D 84 2.0 49 4.58 20 8.32 3.08 1.95–4.84
Unknown 96 4.8 43 2.66 27 5.48 1.99 1.27–3.12
Grade
Well differentiated 33 2.7 47 2.58 34 5.72 Reference
Moderately well
differentiated
339 23.5 7 1.24 11 3.51 1.09 0.76–1.56
Poorly differentiated 76 3.8 118 2.25 89 4.26 1.16 0.76–1.75
Unknown 107 5.2 32 2.90 23 5.81 1.18 0.78–1.76
Smoking
No 513 33.2 182 2.24 148 4.56 Reference
Yes 42 2.0 22 3.53 9 5.74 1.01 0.72–1.42
BMI
Underweight 9 0.6 4 2.59 2 4.50 0.96 0.49–1.91
Ideal 118 7.9 44 2.30 36 4.77 Reference
Overweight 141 8.5 47 2.41 38 4.84 1.11 0.87–1.42
Obese 44 2.9 16 2.52 11 4.59 1.04 0.74–1.48
Morbidly obese 21 0.7 13 7.49 3 9.60 1.98 1.24–3.16
Missing 222 14.5 80 2.03 67 4.27 1.31 0.90–1.90
Age (years)
< 40 6 0.5 1 0.93 1 2.01 Reference
40–49 27 1.8 11 3.01 10 6.37 1.28 0.53–3.10
50–59 79 5.6 33 2.79 16 4.37 1.23 0.53–2.82
60–69 163 9.9 53 2.41 46 4.95 1.46 0.64–3.32
70–79 204 12.1 82 2.70 61 5.31 1.52 0.67–3.46
80–89 76 5.4 24 1.24 23 3.08 1.17 0.50–2.72
Comorbidity
0 257 15.5 99 2.35 73 4.72 Reference
Score
1–3 276 18.2 100 2.41 80 4.76 1.04 0.85–1.28
≥4 22 1.5 5 1.29 4 2.59 1.15 0.89–1.47
Surgery
Elective 337 25.4 96 1.81 93 3.80 Reference
Emergency 115 4.8 48 3.29 37 6.89 1.43 1.15–1.78
Other/unknown 1 0.0 0 0.00 1 11.11 1.10 0.15–7.86
None 102 5.0 60 3.10 26 5.62 1.12 0.89–1.43
Chemotherapy
No 370 27.1 145 2.13 104 4.21 Reference
Yes 185 8.1 59 2.88 53 5.88 1.39 1.14–1.69
BMI, body mass index; CI, confidence interval; HR, hazard ratio.
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with identification of operative procedures and chemother-
apy from secondary care, along with the definition of VTE
in a validated manner from primary [15] and secondary
care, and in that sense is uniquely placed to quantify VTE
risk accurately by these variables. However, Dukes stage
was not universally recorded for all patients in the cohort,
and, in particular, we were unable to classify Stage 1
patients as either Dukes A or Dukes B when this was miss-
ing, and therefore excluded these patients from analyses
that were reliant on stage. Nevertheless, the overall propor-
tions of patients in each stage were reasonably similar to
national data, with the exception of an increased propor-
tion with Dukes D and unknown stage [18]. There may
therefore be some misclassification of Dukes stage, particu-
larly between the Dukes A and B cancers, which could
have resulted in higher than expected VTE rates in
Dukes A patients, leading to an underestimate of the rela-
tive risk of VTE in the other groups, and possibly explain-
ing the use of chemotherapy in a small number of Dukes A
patients. This would not have biased the observed absolute
0.08
0.06
0.04
0.02
0.00
0
Number at risk A
A
641 605 586 568 544
B
C
Unknown stage
D
B
2735 2392 2269 2147 2029
C 2536 2121 1880 1674 1505
D 1490 796 554 390 287
X 2289 1193 947 795 692
0.5
Time since diagnosis (years)
1 1.5 2
Fig. 2. Rate of venous thromboembolism by Dukes stage from time
of diagnosis.
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Fig. 3. Rate of venous thromboembolism in surgical and non-surgical patients, stratified by Dukes stage.
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rates in Dukes B and C patients. The recording of surgical
intervention is known to be reasonably accurate in second-
ary-care data in England [19], but separating out patients
undergoing palliative and curative surgery and receiving
chemotherapy in the Dukes D group is not possible. We
therefore excluded them from our stratified analysis of
stage and chemotherapy. The size of the secondary-care
center may play a role in the outcome of colorectal cancer;
however, we were unable to account for the size of the sec-
ondary-care center treating patients within this dataset.
Although, in our analysis, we were unable to identify those
patients receiving thromboprophylaxis at and around the
time of surgery during the study period (1997–2006), there
were no recommendations for prolonged thromboprophy-
laxis following surgery in the UK, as this was only intro-
duced in 2010, so patients would, at most, have received
low molecular weight heparin while they were inpatients
following their surgery [2]. Also, rates of thromboprophy-
laxis at this time were low, with the ENDORSE study esti-
mating that only 50% of patients received appropriate
thromboprophylaxis [20].
Other literature
Our overall absolute rate of VTE of 15.8 per 1000 person-
years is very similar to those in previous studies on the sub-
ject, as is our observation that rates vary markedly by some
measure of severity of disease [21]. Only one prior study, in
Asian patients, has reported rates by stage of disease, and
found that patients with stage IV disease had a 5.8%
cumulative incidence of VTE at 6 months [8], which is simi-
lar to the 4.6% cumulative incidence that we found for
Dukes D patients. Some prior reports have suggested that
patients undergoing surgery have a decreased risk of VTE
as compared with patients not undergoing surgery [6,7,22],
but we found this only for Dukes C and D patients. This
probably reflects the fact that patients not undergoing sur-
gery generally have more advanced disease or other comor-
bidities that preclude surgery [7]. In contrast, in a recent
study of VTE risk following abdominal surgery among
cancer patients, an increased risk was observed [23].
Previous population-based studies have lacked good
data on the effect of chemotherapy and the risk of VTE
[7]. The majority have focused on high-risk populations
or mixed populations of cancer patients, and have not
reported results for patients with colorectal cancer and
receiving chemotherapy separately [6,9–11,24]. Choi et al.
did report an increased incidence of VTE in patients with
colorectal cancer receiving palliative chemotherapy as
compared with those not receiving chemotherapy, but did
not stratify their results by stage of disease or surgical
intervention [8].
The timing of VTE following surgery has not previ-
ously been addressed, with studies reporting rates from
Table 3 Interaction between chemotherapy and Dukes stage
Rate
(per 1000
person-years) 95% CI HR* 95% CI
No chemotherapy
Dukes A 6.4 4.1–10.2 0.84 0.50–1.40
Dukes B 8.6 6.9–10.5 Reference
Dukes C 18.4 14.9–22.7 1.92 1.42–2.60
Chemotherapy
Dukes A 15.7 5.9–41.7 2.00 0.73–5.48
Dukes B 17.8 12.6–25.0 2.05 1.36–3.10
Dukes C 19.8 15.7–25.0 2.17 1.56–3.01
CI, confidence interval; HR, hazard ratio. *Adjusted for site (colon/
rectum), grade, smoking, body mass index, age, comorbidity (Charl-
son), and surgery admission method.
Table 4 Cumulative incidence of venous thromboembolism (VTE) following surgery by Dukes stage and chemotherapy
Start
number
28 days from surgery 90 days from surgery 180 days from surgery
Events
(0–28
days)
Cumulative
% 95% CI
Events
(28–90 days)
Cumulative
% 95% CI
Events
(90–180 days)
Cumulative
% 95% CI
All patients* 4963 27 0.54 0.37–0.78 29 1.13 0.87–1.46 23 1.62 1.30–2.01
All patients*
Dukes A 537 4 0.74 0.28–1.95 0 0.74 0.28–1.95 0 0.74 0.28–1.95
Dukes B 2316 10 0.43 0.23–0.79 15 1.08 0.73–1.60 7 1.40 0.99–1.97
Dukes C 2110 13 0.60 0.35–1.04 14 1.28 0.88–1.87 16 2.09 1.55–2.81
No chemotherapy
Dukes A 485 4 0.82 0.31–2.16 0 0.82 0.31–2.16 0 0.82 0.31–2.16
Dukes B 1947 8 0.40 0.20–0.81 12 1.03 0.67–1.59 4 1.25 0.84–1.85
Dukes C 1282 8 0.61 0.30–1.21 10 1.41 0.89–2.24 4 1.76 1.16–2.67
Chemotherapy
Dukes A 52 0 0.00 0.00–0.00 0 0.00 0.00–0.00 0 0.00 0.00–0.00
Dukes B 369 2 0.54 0.14–2.15 3 1.36 0.57–3.23 3 2.18 1.10–4.32
Dukes C 828 5 0.60 0.25–1.44 4 1.08 0.57–2.07 12 2.55 1.67–3.89
CI, confidence interval. *Patients with no surgery excluded. This analysis includes Dukes A, B or C patients who underwent surgery and had
not had a VTE event prior to surgery. The follow-up time commenced at the date of surgery.
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the date of diagnosis rather than time of surgery, or pub-
lishing rates on multiple types of surgery and cancer
[8,23]; and nor have stratified estimates been presented
for the risk of chemotherapy by stage among patients
undergoing surgery with curative intent. The latter infor-
mation is critical in allowing clinicians to decide on the
optimum duration of prophylaxis to minimize the risk of
VTE for individual patients. Importantly, we found that,
in Dukes A patients, the increased risk was confined to
the 28 days following surgery. This may be attributable
to a relatively lower tumor burden, given the early stage
of disease, along with a simpler operative intervention,
owing to no involvement of other structures and the lack
of chemotherapy given postoperatively. In contrast,
Dukes B and C patients continued to have an increase in
risk up to 180 days postoperatively, and this was
increased further in those receiving chemotherapy, with a
two-fold increased risk of VTE as compared with
Dukes B patients who only underwent surgery.
Clinical significance
There are ~ 40 000 new diagnoses of colorectal cancer
each year in the UK and 143 000 in the USA. At our
overall reported incidence of VTE of 5.5%, this repre-
sents potentially over 2200 and 7800 preventable VTEs in
these populations. However, choosing which patients to
administer prophylaxis to and when requires information
on VTE risk by stage of disease, treatment given, and the
duration of the risk. Current international guidelines
focus on extended prevention of VTE only in the immedi-
ate postoperative period (up to 28 days) for patients with
colorectal cancer, and these lack a sound evidence base.
Indeed, some authors have questioned the need to con-
tinue thromboprophylaxis to 28 days for all patients
undergoing resection, and have focused instead on the
role of laparoscopy and enhanced recovery in potentially
reducing VTE risk [25]. Our finding that VTE risk follow-
ing surgery in Dukes A patients was limited to the first
28 days suggests that current guidance is reasonable in
this group, and, given evidence from other studies, there
may be scope to reduce the duration of prophylaxis fur-
ther [25]. Importantly, however, we have shown that the
risk following surgery in Dukes B and C patients persists
for at least 6 months following surgery, with the greatest
risk occurring in those receiving chemotherapy. There-
fore, it may be the case that, among these patients, we
could identify high-risk patients who may benefit from a
further extension of prophylaxis beyond 28 days postop-
eratively to balance the risks of extended prophylaxis
against the potential harms of a VTE.
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